| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206895 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(9 years from now) | |
| US11013703 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(9 years from now) | |
| US11850222 | AZURITY | Sotalol compositions and uses of the same |
Nov, 2034
(10 years from now) | |
| US9724297 | AZURITY | Sotalol compositions and uses of the same |
Aug, 2035
(11 years from now) | |
Sotylize is owned by Azurity.
Sotylize contains Sotalol Hydrochloride.
Sotylize has a total of 4 drug patents out of which 0 drug patents have expired.
Sotylize was authorised for market use on 22 October, 2014.
Sotylize is available in solution;oral dosage forms.
Sotylize can be used as indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening, sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm.
The generics of Sotylize are possible to be released after 31 August, 2035.
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening; Sotylize is indicated for the maintenanc...
Dosage: SOLUTION;ORAL
SOTYLIZE family patents
